Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19

The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing acute respiratory distress syndrome (ARDS). This process is an inflammatory picture, involving an NLRP3 inflamosome-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Jiménez, Alejandro, Rubio-Romero, Esteban, Marenco de la Fuente, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2021
Materias:
Artículo Especial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183956/
http://dx.doi.org/10.1016/j.reuma.2020.04.009
_version_ 1783526516177502208
author Muñoz-Jiménez, Alejandro
Rubio-Romero, Esteban
Marenco de la Fuente, José Luis
author_facet Muñoz-Jiménez, Alejandro
Rubio-Romero, Esteban
Marenco de la Fuente, José Luis
author_sort Muñoz-Jiménez, Alejandro
collection PubMed
description The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing acute respiratory distress syndrome (ARDS). This process is an inflammatory picture, involving an NLRP3 inflamosome-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. Anakinra is a potent biological drug, capable of blocking this IL-1ß. We propose its use in controlling ARDS secondary to COVID-19 infection.
format Online
Article
Text
id pubmed-7183956
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología.
record_format MEDLINE/PubMed
spelling pubmed-71839562020-04-27 Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19 Muñoz-Jiménez, Alejandro Rubio-Romero, Esteban Marenco de la Fuente, José Luis Reumatol Clin Artículo Especial The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing acute respiratory distress syndrome (ARDS). This process is an inflammatory picture, involving an NLRP3 inflamosome-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. Anakinra is a potent biological drug, capable of blocking this IL-1ß. We propose its use in controlling ARDS secondary to COVID-19 infection. Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2021 2020-04-27 /pmc/articles/PMC7183956/ http://dx.doi.org/10.1016/j.reuma.2020.04.009 Text en © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Artículo Especial
Muñoz-Jiménez, Alejandro
Rubio-Romero, Esteban
Marenco de la Fuente, José Luis
Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19
title Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19
title_full Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19
title_fullStr Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19
title_full_unstemmed Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19
title_short Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19
title_sort propuesta de uso de anakinra en el distrés respiratorio agudo secundario a covid-19
topic Artículo Especial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183956/
http://dx.doi.org/10.1016/j.reuma.2020.04.009
work_keys_str_mv AT munozjimenezalejandro propuestadeusodeanakinraeneldistresrespiratorioagudosecundarioacovid19
AT rubioromeroesteban propuestadeusodeanakinraeneldistresrespiratorioagudosecundarioacovid19
AT marencodelafuentejoseluis propuestadeusodeanakinraeneldistresrespiratorioagudosecundarioacovid19

Ejemplares similares